Journal article
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
A Sonnenblick, M Salmon-Divon, R Salgado, E Dvash, N Pondé, T Zahavi, A Salmon, S Loibl, C Denkert, H Joensuu, L Ameye, G Van den Eynden, PL Kellokumpu-Lehtinen, A Azaria, S Loi, S Michiels, F Richard, C Sotiriou
International Journal of Cancer | WILEY | Published : 2020
DOI: 10.1002/ijc.32859
Abstract
We investigated the value of reactive stroma as a predictor for trastuzumab resistance in patients with early HER2-positive breast cancer receiving adjuvant therapy. The pathological reactive stroma and the mRNA gene signatures that reflect reactive stroma in 209 HER2-positive breast cancer samples from the FinHer adjuvant trial were evaluated. Levels of stromal gene signatures were determined as a continuous parameter, and pathological reactive stromal findings were defined as stromal predominant breast cancer (SPBC; ≥50% stromal) and correlated with distant disease-free survival. Gene signatures associated with reactive stroma in HER2-positive early breast cancer (N = 209) were significant..
View full abstractGrants
Awarded by Breast Cancer Research Foundation
Funding Acknowledgements
We would like thank Amin Emad (http://www.ece.mcgill.ca/~aemad2) for his assistance with ProGENI.A.S. is supported by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA) and from the Israeli Cancer Research Association (2017-0140). The Parasol Center for Women's Cancer Research, The Parasol Foundation. CS is supported by the Breast Research Cancer Foundation (BCRF). R.S. is supported by a grant from the Breast Cancer Research Foundation (BCRF 17-194).